Axiom Bio is a South San Francisco startup that uses AI and large-scale lab data to predict and explain drug toxicity, especially liver injury, early in drug development. It profiles tens of thousands of molecules in human cell assays and links the results to clinical outcomes to help pharma and biotech teams avoid toxicity failures.